Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1975 7
1976 4
1977 2
1979 2
1980 5
1981 4
1982 1
1983 9
1984 4
1985 9
1986 5
1987 10
1988 8
1989 12
1990 22
1991 20
1992 18
1993 22
1994 29
1995 20
1996 19
1997 15
1998 27
1999 25
2000 25
2001 24
2002 22
2003 28
2004 40
2005 34
2006 37
2007 27
2008 29
2009 37
2010 38
2011 39
2012 36
2013 63
2014 58
2015 48
2016 49
2017 59
2018 61
2019 60
2020 47
2021 54
2022 53
2023 46
2024 57
2025 60
2026 15

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,308 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.
Scully M, Cataland SR, Peyvandi F, Coppo P, Knöbl P, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Callewaert F, Biswas D, De Winter H, Zeldin RK; HERCULES Investigators. Scully M, et al. N Engl J Med. 2019 Jan 24;380(4):335-346. doi: 10.1056/NEJMoa1806311. Epub 2019 Jan 9. N Engl J Med. 2019. PMID: 30625070 Free article. Clinical Trial.
Caplacizumab, an anti-von Willebrand factor humanized, bivalent variable-domain-only immunoglobulin fragment, inhibits interaction between von Willebrand factor multimers and platelets. ...The primary outcome was the time to normalization of the platelet count, with …
Caplacizumab, an anti-von Willebrand factor humanized, bivalent variable-domain-only immunoglobulin fragment, inhibits interaction be …
Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study.
Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, Pessoa V, Gualandro S, Füreder W, Ptushkin V, Rottinghaus ST, Volles L, Shafner L, Aguzzi R, Pradhan R, Schrezenmeier H, Hill A. Lee JW, et al. Blood. 2019 Feb 7;133(6):530-539. doi: 10.1182/blood-2018-09-876136. Epub 2018 Dec 3. Blood. 2019. PMID: 30510080 Free PMC article. Clinical Trial.
Patients with lactate dehydrogenase (LDH) 1.5 times the upper limit of normal and at least 1 PNH symptom were randomized 1:1 to receive ravulizumab or eculizumab for 183 days (N = 246). Coprimary efficacy end points were proportion of patients remaining transfusion-free a …
Patients with lactate dehydrogenase (LDH) 1.5 times the upper limit of normal and at least 1 PNH symptom were randomized 1:1 to rece …
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.
Peyvandi F, Scully M, Kremer Hovinga JA, Cataland S, Knöbl P, Wu H, Artoni A, Westwood JP, Mansouri Taleghani M, Jilma B, Callewaert F, Ulrichts H, Duby C, Tersago D; TITAN Investigators. Peyvandi F, et al. N Engl J Med. 2016 Feb 11;374(6):511-22. doi: 10.1056/NEJMoa1505533. N Engl J Med. 2016. PMID: 26863353 Free article. Clinical Trial.
METHODS: Caplacizumab, an anti-von Willebrand factor humanized single-variable-domain immunoglobulin (Nanobody), inhibits the interaction between ultralarge von Willebrand factor multimers and platelets. ...The primary end point was the time to a response, defined as confi …
METHODS: Caplacizumab, an anti-von Willebrand factor humanized single-variable-domain immunoglobulin (Nanobody), inhibits the interac …
Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta-analysis.
Zuhair M, Smit GSA, Wallis G, Jabbar F, Smith C, Devleesschauwer B, Griffiths P. Zuhair M, et al. Rev Med Virol. 2019 May;29(3):e2034. doi: 10.1002/rmv.2034. Epub 2019 Jan 31. Rev Med Virol. 2019. PMID: 30706584
Cytomegalovirus (CMV) infection does not usually produce symptoms when it causes primary infection, reinfection, or reactivation because these three types of infection are all controlled by the normal immune system. However, CMV becomes an important pathogen in individuals …
Cytomegalovirus (CMV) infection does not usually produce symptoms when it causes primary infection, reinfection, or reactivation because the …
Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome.
Jacobsen A, Olabi B, Langley A, Beecker J, Mutter E, Shelley A, Worley B, Ramsay T, Saavedra A, Parker R, Stewart F, Pardo Pardo J. Jacobsen A, et al. Cochrane Database Syst Rev. 2022 Mar 11;3(3):CD013130. doi: 10.1002/14651858.CD013130.pub2. Cochrane Database Syst Rev. 2022. PMID: 35274741 Free PMC article.
In addition to tertiary-level supportive care, various systemic therapies have been used including glucocorticoids, intravenous immunoglobulins (IVIGs), cyclosporin, N-acetylcysteine, thalidomide, infliximab, etanercept, and plasmapheresis. ...Cyclosporin versus IVIG It i …
In addition to tertiary-level supportive care, various systemic therapies have been used including glucocorticoids, intravenous immunoglo …
Intravenous Immunoglobulin Alone for Coronary Artery Lesion Treatment of Kawasaki Disease: A Randomized Clinical Trial.
Kuo HC, Lin MC, Kao CC, Weng KP, Ding Y, Han Z, Chen CJ, Jan SL, Chien KJ, Ko CH, Lin CY, Lei WT, Guo MM, Yang KD, Sylvester KG, Whitin JC, Tian L, Chubb H, Ceresnak SR, McElhinney D, Cohen HJ, Ling XB. Kuo HC, et al. JAMA Netw Open. 2025 Apr 1;8(4):e253063. doi: 10.1001/jamanetworkopen.2025.3063. JAMA Netw Open. 2025. PMID: 40178858 Free PMC article. Clinical Trial.
IMPORTANCE: Aspirin (acetylsalicylic acid) and intravenous immunoglobulin (IVIG) are standard treatments for Kawasaki disease (KD) to reduce coronary artery lesions (CALs). ...Data analysis was performed using chi2 tests for categorical variables; independent t tests for c …
IMPORTANCE: Aspirin (acetylsalicylic acid) and intravenous immunoglobulin (IVIG) are standard treatments for Kawasaki disease (KD) to …
Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial.
Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, Kato T, Hara T, Hamaoka K, Ogawa S, Miura M, Nomura Y, Fuse S, Ichida F, Seki M, Fukazawa R, Ogawa C, Furuno K, Tokunaga H, Takatsuki S, Hara S, Morikawa A; RAISE study group investigators. Kobayashi T, et al. Lancet. 2012 Apr 28;379(9826):1613-20. doi: 10.1016/S0140-6736(11)61930-2. Epub 2012 Mar 8. Lancet. 2012. PMID: 22405251 Clinical Trial.
Patients with severe Kawasaki disease were randomly assigned by a minimisation method to receive either intravenous immunoglobulin (2 g/kg for 24 h and aspirin 30 mg/kg per day) or intravenous immunoglobulin plus prednisolone (the same intravenous immunoglobulin …
Patients with severe Kawasaki disease were randomly assigned by a minimisation method to receive either intravenous immunoglobulin (2 …
Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial.
Röth A, Berentsen S, Barcellini W, D'Sa S, Jilma B, Michel M, Weitz IC, Yamaguchi M, Nishimura JI, Vos JMI, Storek M, Wong N, Patel P, Jiang X, Vagge DS, Wardęcki M, Shafer F, Lee M, Broome CM. Röth A, et al. Blood. 2022 Sep 1;140(9):980-991. doi: 10.1182/blood.2021014955. Blood. 2022. PMID: 35687757 Free PMC article. Clinical Trial.
Sutimlimab, a first-in-class humanized immunoglobulin G4 (IgG4) monoclonal antibody that selectively inhibits the classical complement pathway at C1s, rapidly halted hemolysis in the single-arm CARDINAL study in recently transfused patients with cold agglutinin disease (CA …
Sutimlimab, a first-in-class humanized immunoglobulin G4 (IgG4) monoclonal antibody that selectively inhibits the classical complemen …
Accuracy of the No-Biopsy Approach for the Diagnosis of Celiac Disease in Adults: A Systematic Review and Meta-Analysis.
Shiha MG, Nandi N, Raju SA, Wild G, Cross SS, Singh P, Elli L, Makharia GK, Sanders DS, Penny HA. Shiha MG, et al. Gastroenterology. 2024 Apr;166(4):620-630. doi: 10.1053/j.gastro.2023.12.023. Epub 2024 Jan 2. Gastroenterology. 2024. PMID: 38176661 Free article.
However, growing evidence suggests that immunoglobulin A (IgA) anti-tissue transglutaminase (tTg) antibody levels 10 times the upper limit of normal (ULN) can accurately predict celiac disease, eliminating the need for biopsy. ...
However, growing evidence suggests that immunoglobulin A (IgA) anti-tissue transglutaminase (tTg) antibody levels 10 times the upper …
1,308 results